Clinical and Genetic Risk Factors for Biofilm-Forming Staphylococcus aureus

Area of Science:

• Microbiology
• Infectious Diseases
• Genetics

Background:

• Biofilm formation by methicillin-resistant Staphylococcus aureus (MRSA) is a significant clinical challenge.
• Understanding the molecular and clinical factors driving MRSA biofilm production is crucial for effective treatment and patient management.

Purpose of the Study:

• To identify molecular and clinical predictors of strong biofilm formation in MRSA isolates.
• To evaluate the association between strong biofilm production and clinical outcomes in patients.

Main Methods:

• Quantification of biofilm production in 182 clinical MRSA isolates.
• Analysis of microbiological toxins, pigmentation, genotypes (MLST, spa types), and patient demographics.
• Logistic regression to determine predictors of strong biofilm formation and their impact on clinical outcomes.

Main Results:

• 25.8% of MRSA isolates produced strong biofilms.
• Strong biofilm producers were associated with MLST CC8 and spa type t008.
• Factors like chemotherapy/immunosuppressants predicted strong biofilm formation, while vancomycin use and high creatinine predicted weaker biofilms.
• Patients with strong biofilm-forming MRSA had higher 90-day readmission rates but lower mortality.

Conclusions:

• Specific MRSA genotypes (e.g., MLST CC8, spa t008) and patient factors (e.g., immunosuppression) are associated with increased biofilm formation.
• Strong biofilm production in MRSA correlates with distinct clinical outcomes, including increased readmissions and decreased mortality.